Shiji Fang | Medicine | Best Researcher Award

Published on by Research Hypothesis

Best Researcher Award

Shiji Fang
Lishui Central Hospital, China

Shiji Fang
Affiliation Lishui Central Hospital
Country China
Scopus ID 57192204982
Documents 91
Citations 2,574
h-index 27
Subject Area Medicine
Event International Research Hypothesis Excellence Award
ORCID 0009-0004-4998-5039

Shiji Fang is a medical researcher affiliated with Lishui Central Hospital in China whose indexed research profile reflects sustained scholarly activity in biomedical and translational medicine. The available Scopus-derived profile records 91 documents, 2,574 citations and an h-index of 27, indicating a substantial body of indexed research and citation activity. [1][2]

Abstract

Shiji Fang’s research profile is situated within medicine and includes a substantial body of indexed scholarly work. The supplied publication record highlights research at the intersection of cancer biology, tumor microenvironment, immunotherapy and nanomedicine. Recent studies address mechanisms and therapeutic approaches involving immunogenic cell death, reactive oxygen species, endoplasmic reticulum stress, cellular senescence, copper homeostasis, ferroptosis, cuproptosis, chemoembolization and MRI-guided therapeutic systems. [1] [2]

Keywords

Shiji Fang; Best Researcher Award; Medicine; cancer research; hepatocellular carcinoma; immunotherapy; nanomedicine; immunogenic cell death; ferroptosis; cuproptosis; tumor biology; therapeutic delivery; translational medicine; oxidative stress; endoplasmic reticulum stress.

Introduction

Contemporary cancer research increasingly integrates molecular oncology with materials science, immunology and targeted therapeutic delivery. Hepatocellular carcinoma in particular presents a complex therapeutic environment in which tumor heterogeneity, immune suppression and resistance mechanisms can limit treatment effectiveness. Research that investigates interactions among tumor cells, immune pathways and therapeutic nanoplatforms therefore forms an important component of translational biomedical investigation.[2] [3]

Research Profile

The supplied Scopus profile identifies Shiji Fang with Author ID 57192204982 and lists Lishui Central Hospital, China, as the institutional affiliation. The profile is associated with the subject area of Medicine and records 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Research characteristics

  • Primary discipline: Medicine.
  • Institutional affiliation: Lishui Central Hospital, China.
  • Scopus Author ID: 57192204982.
  • Indexed documents: 91.
  • Reported citations: 2,574.
  • Reported h-index: 27.
  • Major themes represented: cancer biology, hepatocellular carcinoma, immunotherapy, nanomedicine and regulated cell-death mechanisms.

Research Contributions

The supplied publications indicate several connected areas of research contribution. One strand examines how natural or bioactive compounds can influence cancer-cell death and stress-response pathways. The 2025 article on astragalin investigates immunogenic cell death in liver cancer in connection with NQO2, reactive oxygen species and endoplasmic reticulum stress. [2]

A second strand concerns the integration of cellular senescence with immune activation. The study published in Advanced Science describes a biomimetic nanomedicine approach designed around senescence-modulated immune activation and its potential relationship with immunotherapy efficacy in hepatocellular carcinoma. [3]

Publications

The following selected publications are taken from the supplied Scopus-derived research information. The list emphasizes recent 2025 articles and includes DOI identifiers where provided.

  1. Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
  2. Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
  3. Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
  4. Corrigendum to “Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma”. Cellular Signalling.

Research Impact

The supplied bibliometric indicators provide a quantitative view of the visibility of the research record. With 2,574 reported citations and an h-index of 27 across 91 indexed documents, the profile demonstrates sustained citation activity within the indexed scholarly literature. [1] Bibliometric measures should nevertheless be interpreted alongside publication quality, methodological rigor, authorship contributions and the substantive influence of individual studies.

Award Suitability

The Best Researcher Award within the International Research Hypothesis Excellence Award framework can be assessed using evidence concerning research productivity, scholarly visibility, thematic contribution and relevance to the broader research community. The supplied profile provides several measurable indicators, including 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Conclusion

Shiji Fang’s supplied academic profile presents an established research record in Medicine, with affiliation to Lishui Central Hospital in China and a Scopus Author ID of 57192204982. The reported 91 documents, 2,574 citations and h-index of 27 provide quantitative indicators of scholarly activity and citation visibility. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Shiji Fang, Author ID 57192204982. Scopus.
    https://www.scopus.com/pages/authors/57192204982
  2. Zheng, L., Zhao, Z., Chen, L., Yang, W., Ercolani, G., Qin, P., Lin, B., Han, M., Weng, Q., Zhang, Y., et al. (2025). Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
    https://doi.org/10.1016/j.freeradbiomed.2025.07.047
  3. Fang, S., Zheng, L., Lin, B., Chen, J., Hou, D., Ding, Y., Han, M., Qin, P., Wang, M., Guo, X., et al. (2025). Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
    https://doi.org/10.1002/advs.202517792
  4. Liang, X., Fang, S., Xin, Y., Lei, J., Wang, W., Wei, Y., Li, W., Li, C., Tang, H., Wei, X., et al. (2025). Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
    https://doi.org/10.1186/s12951-025-03722-2
  5. Chen, M., Chen, Y., Chen, W., Chen, X., Guo, X., Yu, J., Guo, X., Wang, M., Zhang, X., Hu, Q., et al. (2025). Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor. Acta Biomaterialia.
    https://doi.org/10.1016/j.actbio.2025.04.042
  6. Chen, X., Zhang, F., Lu, C., Wu, R., Yang, et al. (2025). Lactate-Fueled Theranostic Nanoplatforms for Enhanced MRI-Guided Ferroptosis Synergistic with Immunotherapy of Hepatocellular Carcinoma. ACS Applied Materials and Interfaces.
    https://doi.org/10.1021/acsami.4c21890

Emrah Can | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award | Professor| Istanbul University | Turkey

Prof. Dr. Emrah Can is a highly accomplished pediatrician and neonatology-focused clinician-scientist recognized for his extensive contributions to neonatal health, pediatric infectious diseases, neonatal sepsis, retinopathy of prematurity, and pediatric critical care. Prof. Dr. Emrah Can completed his medical training at Istanbul University Faculty of Medicine, followed by his medical specialization in Child Health and Diseases at Health Sciences University, İstanbul Bağcılar Training and Research Hospital, where he developed strong clinical expertise in neonatal nutrition, early sepsis biomarkers, high-risk neonatal monitoring, and pediatric intensive care. He progressed academically to the ranks of Associate Professor and Professor through consistent research productivity, clinical excellence, and mentorship. Throughout his career, Prof. Dr. Emrah Can has supervised numerous pediatric specialization theses focused on neonatal sepsis biomarkers, MRSA carriage among hospitalized children, melatonin levels in early sepsis, prognostic tools for pediatric traumatic brain injury, differentiation of lower respiratory tract infection and colonization in tracheostomized children, fetal malnutrition indicators, and hyperbilirubinemia-related risk factors, demonstrating his commitment to developing evidence-based pediatric protocols and training the next generation of pediatric specialists. His research interests include neonatal immunology, inflammation markers, nutritional interventions for premature infants, oxygen affinity biomarkers, neonatal thrombosis, and innovative hypothesis-driven models for predicting neonatal morbidity. His research skills include statistical analysis, advanced clinical data interpretation, hypothesis modeling, neonatal diagnostic model development, and interdisciplinary collaboration. Prof. Dr. Emrah Can has authored impactful publications in reputable journals such as Medical Hypotheses, International Ophthalmology, European Journal of Pediatrics, Pediatric Cardiology, and Journal of Paediatrics and Child Health, contributing significantly to early detection strategies for NEC, ROP, neonatal thrombosis, and hematologic alterations in neonates. His scientific memberships reflect his professional commitment, including active participation in the Pediatric Allergy and Asthma Academy Association, Turkish National Pediatric Association, Child Friends Association, and Turkish Neonatology Association. He has also served in academic administrative roles, including program head positions that highlight his leadership in medical education. Prof. Dr. Emrah Can has received recognition for his academic achievements, research contributions, and involvement in pediatric healthcare improvement initiatives. Overall, Prof. Dr. Emrah Can demonstrates exceptional clinical acumen, research innovation, collaborative engagement, and leadership in pediatric and neonatal medicine, positioning him as a scholar whose contributions continue to shape evidence-based neonatal care, advance scientific understanding of pediatric diseases, and improve health outcomes for vulnerable newborn populations.

Profile:  scopus | ORCID

Featured Publications

  1. Can, E. (2025). Development of a scoring model integrating inflammatory markers for predicting ROP in preterm neonates. International Ophthalmology.

  2. Can, E. (2025). Postnatal hemoglobin P50 as a surrogate marker for hypoxia-driven NEC in preterm infants: A mechanistic hypothesis. Medical Hypotheses.

  3. Can, E. (2025). Phototherapy modifies hematologic markers without inducing inflammation in neonates: A retrospective observational study. European Journal of Pediatrics.

  4. Can, E. (2025). Could parabiotics safely enhance immune maturation and mitigate NEC/sepsis in preterm neonates? Medical Hypotheses.

  5. Can, E. (2025). Early haemoglobin oxygen affinity as a hypothesis-generating marker for retinopathy of prematurity risk in preterm infants. Journal of Paediatrics and Child Health.

  6. Can, E. (2025). Neonatal portal vein thrombosis: A case series from a tertiary NICU. Pediatric Cardiology.

 

Tracey Young-Sharma | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Tracey Young-Sharma | Medicine and Health Sciences | Best Researcher Award

Dr Tracey Young-Sharma, Ministry of Health and Medical Service FIji, Fiji

Dr. Tracey Young-Sharma is an accomplished physician specializing in internal medicine and antimicrobial resistance (AMR). She holds a Masters of Medicine from Fiji National University (2019) and has been awarded the ASID GOLD Medal. Currently an AMR consultant for the World Health Organization, Dr. Young-Sharma has held various roles, including Consultant Physician and Registrar at CWM Hospital. She has contributed to multiple studies on antimicrobial resistance and its impact in Fiji, with notable publications in The Lancet and JGAR. Dr. Young-Sharma is also the Chairperson of the Infection Prevention Control Committee at CWMH. 🏥🦠📚🌍

Publication Profile

Scopus

Education

Dr. Tracey Young-Sharma is a highly accomplished medical professional with a strong background in Internal Medicine. She completed her Masters of Medicine in Internal Medicine at Fiji National University in 2019. Prior to that, she earned a Postgraduate Diploma in Internal Medicine in 2016 and a Bachelor’s degree in Medicine and Surgery from the Fiji School of Medicine in 2010. Dr. Young-Sharma has been recognized for her excellence in the field, receiving the prestigious Australian Society of Infectious Disease (ASID) GOLD Medal Award 🏅💉. Her dedication to improving healthcare continues to inspire and impact the medical community. 👩‍⚕️🌟

Experience

Dr. Tracey Young-Sharma is an AMR consultant for the World Health Organisation (WHO) since August 2024 🌍. Previously, she served as a Consultant Physician at CWM Hospital (2022-2024) 🏥 and as a Registrar at the same hospital from 2016 to 2021. Prior to that, she worked as a Registrar in Internal Medicine at Labasa Hospital in 2015 🩺. Dr. Young-Sharma began her career as a Medical Officer at Levuka Hospital and Koro Health Centre (2012-2014) 🏥 and completed her internship at CWM Hospital in 2011. Her extensive experience spans various medical roles, contributing to healthcare development. 👩‍⚕️🌿

Professional Memberships 

Dr. Tracey Young-Sharma is a dedicated healthcare professional with strong affiliations in the medical field. She is an Associate Member of the Internal Medicine Society of Australia and New Zealand and a member of the Internal Medicine Organisation of the Pacific. Additionally, Dr. Young-Sharma is part of the International Women’s Association, the Fiji Medical Association, and the Australasian College of Infection Prevention and Control. In 2022, she served as the Chairperson of the Infection Prevention and Control Committee at CWMH. Her active roles reflect her commitment to advancing healthcare and fostering collaboration in the medical community. 🌍👩‍⚕️💉🩺

Research Focus

Dr. Tracey Young-Sharma’s research primarily focuses on antimicrobial resistance (AMR), particularly in resource-limited settings like Fiji. Her work involves genomic surveillance and epidemiological studies to understand the spread of carbapenem-resistant organisms and other multidrug-resistant pathogens. Dr. Young-Sharma’s studies also emphasize the impact of AMR on healthcare outcomes, including attributable mortality and length of hospital stays. She is also involved in improving healthcare workers’ knowledge and readiness to combat AMR through intervention studies. Her research aims to inform public health strategies and healthcare policies in the context of global AMR challenges. 🦠🔬🌍👩‍🔬💉

Publication Top Notes

Successful management of a multi-species outbreak of carbapenem-resistant organisms in Fiji: a prospective genomics-enhanced investigation and response

Knowledge, attitudes, and readiness about critical antimicrobial resistant organisms among healthcare workers at colonial war memorial hospital in Fiji: a pre and post intervention study

The epidemiology of enterococci in a tertiary hospital and primary healthcare facilities in Fiji (2019–2022)

The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019–2022

Attributable mortality and excess length of stay associated with third-generation cephalosporin-resistant Enterobacterales bloodstream infections: a prospective cohort study in Suva, Fiji

Epidemiology, antimicrobial resistance and outcomes of Staphylococcus aureus bacteraemia in a tertiary hospital in Fiji: A prospective cohort study